We describe rapid and sustained response of a 44-year-old woman with steroid-refractory adult-onset Still's disease (AOSD) to treatment with the interleukin 1 (IL-1) receptor antagonist analcinra as a first-line immuno-suppressive therapy. The fast mode of action compared to conventional ...